{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T22:21:20Z","timestamp":1769206880080,"version":"3.49.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Voriconazole is mainly used to treat progressive and potentially life-threatening infections in immunocompromised patients. The adverse drug reactions related to voriconazole are varied. In some rare cases, the use of voriconazole can result in myelodysplastic syndrome (MDS)-like adverse reactions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>Here, we present a rare case of systemic lupus erythematosus patient with a fungal infection that developed MDS-like adverse reactions after treatment with voriconazole. The patient was admitted to the hospital because of 3\u2009days of chest tightness and dyspnea. After the admission, the patient\u2019s sputum culture showed <jats:italic>Candida albicans<\/jats:italic> infection, and voriconazole was prescribed to be taken orally. After using voriconazole, drug-related adverse reactions such as visual impairment, nausea, vomiting, hiccup, middle and lower abdominal pain, disorders of consciousness, delirium, hallucination, slow response, and subcutaneous ecchymosis appeared, as well as the gradually increased serum creatinine, oliguria, and aggravated lower limb edema. In addition, there was a decrease in peripheral blood cells, and MDS-like changes in bone marrow were indicated by bone marrow biopsy. After discontinuing voriconazole, drug-related adverse symptoms disappeared, and hematocytopenia and the changes in MDS were significantly improved, which was confirmed by a subsequent bone marrow puncture at a 6\u2009months interval.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This case reminded us that when using voriconazole for treatment, individual differences in patients should be considered, and the blood concentration of voriconazole should be closely monitored. Otherwise, potential drugs that affect voriconazole metabolism should be noted, and related adverse symptoms of patients should be closely observed during medication to reduce the occurrence of adverse drug events.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1286649","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T07:59:11Z","timestamp":1702022351000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Myelodysplastic syndrome-like response after voriconazole treatment of systemic lupus erythematosus complicated with fungal infection: a case report"],"prefix":"10.3389","volume":"10","author":[{"given":"Guang-Liang","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Su","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-Yan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangchen","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Qiu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/ctr.12834","article-title":"Adverse effects of voriconazole: over a decade of use","volume":"30","author":"Levine","year":"2016","journal-title":"Clin Transpl"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1093\/jac\/dkw045","article-title":"Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis","volume":"71","author":"Jin","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"899886","DOI":"10.3389\/fmed.2022.899886","article-title":"Case report: Vancomycin-associated tubulointerstitial nephritis in clinical practice-case report and review of literature","volume":"9","author":"Kannan","year":"2022","journal-title":"Front Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1086\/324620","article-title":"Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis","volume":"34","author":"Denning","year":"2002","journal-title":"Clin Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s10096-011-1425-5","article-title":"An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole","volume":"31","author":"Jacobs","year":"2012","journal-title":"J Clin Microbiol Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1128\/AAC.00626-12","article-title":"Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s12281-015-0219-0","article-title":"Therapeutic drug monitoring and genotypic screening in the clinical use of voriconazole","volume":"9","author":"Moriyama","year":"2015","journal-title":"Curr Fungal Infect Rep"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1093\/infdis\/jiu017","article-title":"Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype","volume":"209","author":"Zonios","year":"2014","journal-title":"J Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"bcr2018226758","DOI":"10.1136\/bcr-2018-226758","article-title":"A rare and serious cause of pancytopenia in a patient with systemic lupus erythematosus: haemophagocytic lymphohistiocytosis","volume":"2018","author":"Almuwaqqat","year":"2018","journal-title":"BMJ Case Rep"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1093\/qjmed\/hcx102","article-title":"Bone marrow involvement in systemic lupus erythematosus","volume":"110","author":"Chalayer","year":"2017","journal-title":"QJM"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"ITC81","DOI":"10.7326\/AITC202006020","article-title":"Systemic lupus erythematosus","volume":"172","author":"Kiriakidou","year":"2020","journal-title":"Ann Intern Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/ajh.20593","article-title":"Bone marrow histological findings in systemic lupus erythematosus with hematologic abnormalities: a clinicopathological study","volume":"81","author":"Voulgarelis","year":"2006","journal-title":"Am J Hematol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"102090","DOI":"10.1016\/j.canep.2021.102090","article-title":"Personal history of autoimmune disease and other medical conditions and risk of myelodysplastic syndromes","volume":"76","author":"Linabery","year":"2022","journal-title":"Cancer Epidemiol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3390\/biom11070928","article-title":"Clinical and immunological biomarkers for systemic lupus erythematosus","volume":"11","author":"Yu","year":"2021","journal-title":"Biomol Ther"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1056\/NEJMra1904794","article-title":"Myelodysplastic syndromes","volume":"383","author":"Cazzola","year":"2020","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1517\/14740338.2015.1014340","article-title":"Therapy-related myelodysplastic syndrome","volume":"14","author":"Candelaria","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000489702","article-title":"Myelodysplastic syndrome updated","volume":"86","author":"Hasserjian","year":"2019","journal-title":"Pathobiology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1684\/abc.2013.0804","article-title":"Myelodysplastic syndrome classification","volume":"71","author":"Ghariani","year":"2013","journal-title":"Ann Biol Clin"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1159\/000488712","article-title":"The molecular pathology of myelodysplastic syndrome","volume":"86","author":"Haferlach","year":"2019","journal-title":"Pathobiology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"10232","DOI":"10.3390\/ijms221910232","article-title":"Molecular targeted therapy and immunotherapy for myelodysplastic syndrome","volume":"22","author":"Lee","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13027-022-00446-y","article-title":"Severe coagulopathy caused by cefminox sodium in a liver cirrhosis patient: a case report","volume":"17","author":"Wu","year":"2022","journal-title":"Infect Agent Cancer"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s13300-017-0357-1","article-title":"Assessing the effect of piperacillin\/tazobactam on hematological parameters in patients admitted with moderate or severe foot infections","volume":"9","author":"Fry","year":"2018","journal-title":"Diabetes Ther"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.4021\/jocmr2009.03.1227","article-title":"Piperacillin\/tazobactam induced myelosuppression","volume":"1","author":"Lee","year":"2009","journal-title":"J Clin Med Res"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1046\/j.1365-2141.1996.d01-1952.x","article-title":"Reversible bone marrow depression by high-dose piperacillin\/tazobactam","volume":"95","author":"Ruiz-Irastorza","year":"1996","journal-title":"Br J Haematol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13256-020-02632-1","article-title":"Meropenem-induced pancytopenia in a preterm neonate: a case report","volume":"15","author":"Hussain","year":"2021","journal-title":"J Med Case Rep"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1286649\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T07:59:13Z","timestamp":1702022353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1286649\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":27,"alternative-id":["10.3389\/fmed.2023.1286649"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1286649","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,7]]},"article-number":"1286649"}}